Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amur Minerals ( (GB:CRTX) ) has provided an announcement.
CRISM Therapeutics Corporation announced significant preclinical findings for its ChemoSeed platform in prostate cancer treatment, showing that sustained administration of docetaxel is more effective than current intermittent dosing methods. This development could enhance treatment efficacy with lower drug doses, reducing side effects. Additionally, CRISM has partnered with Ulster University through a prestigious doctoral award to further develop personalized treatment strategies, potentially accelerating the path to clinical trials and improving patient outcomes.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based clinical-stage drug delivery company specializing in the localized and sustained delivery of chemotherapy drugs. Their lead product, ChemoSeed, is designed to improve cancer treatment outcomes by delivering therapeutic concentrations of chemotherapy directly into tumors or resection margins, particularly for solid tumors like glioblastoma.
Average Trading Volume: 56,121
Technical Sentiment Signal: Sell
Current Market Cap: £4.4M
Learn more about CRTX stock on TipRanks’ Stock Analysis page.